I was never able to work since I was diagnosed sz 9 years ago. After taking 40-60g glycine with soy milk daily, I was able to work continuously for 6 months until my pdr prescribed Wellbutrin which broke my concentration at work even after stopping. It made me paranoid worsening positive symptoms. I had stopped glycine a couple of weeks after starting work due to nausea.
I started glycine again now but I take 10g this time no nausea daily, my family are telling me that I improved, I am talking more and keeping interesting conversations instead of staying in bed all day. I am more alert and feel more energetic. Also I am eating much less and feel full because its an amino acid, a component of protein which makes you feel full. I hope I will be able to work soon…
“Glycine treatment was associated with an 8-fold increase in serum glycine levels, similar to that observed previously. A significant 34% reduction in negative symptoms was observed during glycine treatment. Serum antipsychotic levels were not significantly altered. Significant clinical effects were observed despite the fact that the majority of subjects were receiving atypical antipsychotics (clozapine or olanzapine). As in earlier studies, improvement persisted following glycine discontinuation.”
How many grams were you taking? I found out that anything more than 10g with a big glass of soy milk gave me nausea. With the 40-60g I sometimes took anti-nausea pills which worked but I prefer not to depend on it if 10g gives the same effect.
Is there any drug in development that stimulates NMDA receptors like glycine? I know Lumateperone acts like glycine at NDMA receptors and is marketed for negative symptoms. I think someone here is on Lumateperone which means its available in the US. It will take several years before reaching Canada.
At least we now know that stimulating NMDA excitatory receptors reduces negative and cognitive symptoms. I have hope in that Lumateperone will improve negatives like they are claiming and like what reasearch showed.
"The Eli Lilly and Company study drug LY2140023 is being studied as a primary antipsychotic and is showing strong recovery rates, especially in the area of negative and cognitive symptoms of schizophrenia. Tardive dyskinesia, diabetes and other standard complications have not been noted.
Other NMDA receptor modulators are being studied and this modality of treatment may once approved as antipsychotic medications gradually replace the current (dopaminergic) antipsychotics.
